Pacira Biosciences, Inc. reiterated earnings guidance for the full year 2024. For the period, the company expects total revenue of $680 million to $705 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.19 USD | +3.11% | -2.69% | -16.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.45% | 1.31B | |
+52.93% | 803B | |
+40.55% | 629B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+17.13% | 244B | |
+1.39% | 226B | |
+6.24% | 164B | |
-4.79% | 155B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira Biosciences, Inc. Reiterates Earnings Guidance for the Full Year 2024